IDEXX Laboratories, Inc. (IDXX) Fair Value 2026

IDXX · In Vitro & In Vivo Diagnostic Substances ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

10.0 /10

32 fundamental signals · 13 models active

Value Trap Risk

(—/100)

Quick Summary — As of 2026-07-13, IDEXX Laboratories, Inc. (IDXX) trades at $564.21, approximately 227% above CirclFi’s Bayesian DCF fair value of $172.60. QOC: 10.0/10. 13/13 models active.

Key Facts

Ticker
IDXX
Price
$564.21
Quality Score
10.0/10
Value Trap Risk
—/100
Models Active
13/13
Last Updated
Strength: Quality Score of 10.0/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Valuation Matrix

13 Intrinsic Value Models vs. Current Price ($564.21)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
$172.60 -69.4%
Earnings Power Value
High Conviction
$98.95 -82.5%
CUCE Ensemble
Low Conviction
$215.71 -61.8%
First Chicago
High Conviction
$283.60 -49.7%

Unlock the Full Matrix

Access 9 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 13 Models →

Cancel anytime · No contracts · Instant access

What Is IDEXX Laboratories, Inc. (IDXX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, IDEXX Laboratories, Inc.'s intrinsic value is estimated at $295.69, suggesting the stock is overvalued at its current price of $564.21. With 11 out of 13 models flagging downside (-47.6% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: Markov DDM targets $1,122.33 (+98.9%), versus Dynamic NAV at $7.24 (-98.7%). This +197.6% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About IDXX?

13 of 13 models are currently active for IDXX. Of these, 1 model suggests upside while 12 models suggest overvaluation. The Bayesian DCF estimates IDXX's intrinsic value at $172.60, implying -69.4% downside from the current price. See which stocks rank higher →

How Does IDXX Rank in In Vitro & In Vivo Diagnostic Substances?

Among 17 In Vitro & In Vivo Diagnostic Substances stocks, IDXX ranks #1 by Quality of Company score. CirclFi's QOC score of 10.0/10 evaluates 32 fundamental signals. A score of 10.0 places IDXX in the top tier.

IDEXX Laboratories, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is IDXX a Value Trap?

The Value Trap algorithm is not active for IDXX. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

13 of 13 models are active for IDEXX Laboratories, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, IDEXX Laboratories, Inc.'s fundamental quality profile registers 10.0/10. This exceptional score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +197.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IDXX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IDXX's 13 active models, average confidence is 45%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy IDEXX Laboratories, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar In Vitro & In Vivo Diagnostic Substances Stocks Should You Also Analyze?

8 related In Vitro & In Vivo Diagnostic Substances stocks with 13-model coverage

Read investment analysis: LNTH · NEOG · ICCC · QDEL · NTLA

Frequently Asked Questions About IDEXX Laboratories, Inc.

What is IDEXX Laboratories, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, IDEXX Laboratories, Inc. (IDXX) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $172.60. The Quality of Company score is 10.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IDXX overvalued or undervalued right now?

At $564.21, 1 of 13 active models suggest IDXX may be undervalued, while 12 indicate potential overvaluation. The assessment depends on which methodology best fits IDEXX Laboratories, Inc.'s business model in In Vitro & In Vivo Diagnostic Substances.

What does a Quality of Company score of 10.0 mean for IDXX?

IDEXX Laboratories, Inc.'s QOC of 10.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on IDXX?

CirclFi analyzes IDXX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 13 of 13 are active for this stock. Read the full methodology →

Is IDXX a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for IDXX at this time. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 13 mathematical frameworks give you clarity on IDXX.

Unlock All 13 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access